FDA’s New Changes to Hormone Replacement Therapy: What You Need to Know

THE FDA’S NEW HORMONE THERAPY CHANGES: WHAT IT MEANS FOR WOMEN AND MEN IN 2025

A Comprehensive Review by Gemini Health & Wellness

A New Era for Hormone Therapy

Hormone replacement therapy has undergone one of the most significant regulatory updates in more than two decades. In late 2025, the U.S. Food and Drug Administration revised the safety labeling, risk language, and core information used in both menopausal hormone therapy and testosterone replacement products. For anyone seeking clarity about estrogen therapy, progesterone therapy, testosterone therapy, or compounded alternatives, these changes represent a major turning point. They modernize the conversation and help align national guidelines with the current scientific evidence.

For years, hormone therapy has been clouded by confusion, fear, and outdated warnings that never fully reflected real-world data. This update from the FDA marks a long-awaited shift, and it fundamentally reshapes how patients and providers can discuss and approach hormone care.

The History Behind the Change

Hormone therapy’s reputation was shaped heavily by the 2002 Women’s Health Initiative study. That large clinical trial led to the creation of a bold black-box warning on estrogen and estrogen-progesterone products. The warning implied broad risks—including breast cancer, stroke, blood clots, and dementia—without fully accounting for the age, timing, and health characteristics of the women in the study.

The average WHI participant was 63 years old, well beyond the menopausal transition, and many already had cardiovascular risk factors. Despite this, the results were generalized to all menopausal women, including those in their 40s and early 50s who were most likely to benefit from hormone therapy. This overgeneralization shaped the medical landscape for decades and discouraged providers and patients from considering treatment.

Over the years, however, continued research demonstrated that the risks and benefits of hormone therapy depend heavily on the age at which treatment is initiated and the window of time since menopause. This accumulated evidence is what prompted the FDA to reassess the long-standing warnings and ultimately update the labeling.

The Black Box Warning: What Changed

One of the most impactful changes in the new FDA guidelines is the substantial revision of the long-standing black-box warning. The previous black box listed concerns about cardiovascular disease, stroke, blood clots, dementia, and breast cancer in stark, alarming language. These warnings often overshadowed patient counseling and contributed to widespread underutilization of hormone therapy—even among ideal candidates.

The FDA’s updated labeling acknowledges that these risks were overstated when applied to younger menopausal women. The agency specifies that women who begin hormone therapy before age 60 or within ten years of menopause have a different and far more favorable risk profile compared to the older WHI participants. By removing or modifying these generalized warnings, the FDA offers a more accurate, balanced understanding of hormone therapy safety.

Importantly, this does not eliminate caution for those with specific contraindications. Instead, it ensures that the language reflects current, evidence-based risk assessments rather than outdated data.

Why the FDA Updated Its Labeling

The FDA’s decision was driven by two decades of rigorous follow-up research that consistently demonstrated significant differences in risk depending on timing. Women who start estrogen therapy closer to menopause tend to have lower cardiovascular risk, reduced clotting risk, and better metabolic outcomes compared to those who start therapy later in life.

This body of evidence supports the modern “window of opportunity” concept in hormone therapy. When started early, hormone therapy can improve vasomotor symptoms, sleep quality, mood stability, weight distribution, cognitive clarity, vaginal comfort, and bone density in a safe and effective manner for most patients. The FDA’s updated labeling now clearly reflects this reality.

These changes highlight the need for individualized assessment rather than blanket avoidance. They encourage providers to consider each patient’s unique risk profile and symptom burden while helping patients make informed decisions without unnecessary fear.

What Stays the Same in Hormone Therapy Safety

Even with the major changes, the FDA continues to emphasize several essential safety considerations. Hormone therapy is still contraindicated for individuals with certain medical histories, such as estrogen-sensitive cancers, active liver disease, unexplained vaginal bleeding, a history of specific clotting disorders, or certain cardiovascular conditions. These guidelines remain unchanged and continue to guide safe prescribing.

The difference is that risk discussions are no longer overshadowed by overly broad warnings. Patients and providers can now engage in a clearer, more nuanced conversation based on age, health status, and symptom severity rather than fear-driven messaging.

Implications for Women Considering Hormone Therapy

For women contemplating hormone therapy, these new FDA changes may provide reassurance and clarity. Hormone therapy is now recognized more accurately as a safe and effective treatment for healthy women in the early stages of menopause who are experiencing significant symptoms such as hot flashes, night sweats, mood fluctuations, insomnia, weight redistributions, cognitive challenges, or vaginal discomfort.

The updated FDA language also brings attention to the safety of local vaginal estrogen, which has minimal systemic absorption and provides substantial relief for women experiencing genitourinary symptoms. Many women have gone untreated for years due to misunderstandings about the risks of estrogen creams or vaginal tablets. The new guidelines may help more patients access these highly effective therapies.

Updated Testosterone Therapy Guidance in 2025

In addition to the menopausal hormone therapy updates, the FDA made major changes to testosterone replacement therapy earlier in 2025. These updates were based on the TRAVERSE trial, a large clinical study that followed thousands of men with confirmed hypogonadism. The results found no increased risk of major cardiovascular events in men undergoing testosterone therapy for medically documented reasons.

This new evidence prompted the FDA to revise the older language that suggested testosterone therapy increased heart attack or stroke risk. The new labeling more accurately reflects the research and reassures patients and providers about the cardiovascular safety of testosterone therapy when used as intended.

The FDA does continue to emphasize that testosterone therapy must be prescribed for diagnosed hypogonadism, not for age-related testosterone decline or general wellness. It also notes the importance of monitoring blood pressure during treatment, as testosterone can increase blood pressure in some individuals.

The Ongoing Discussion About Compounded “Bioidentical” Hormones

The recent FDA updates did not grant any new validation or regulatory approval for compounded hormone therapy. The agency reaffirmed that compounded hormones remain unapproved, unregulated in the same manner as commercial products, and lacking standardized clinical evidence. Estriol-containing compounded products also remain unapproved.

While compounded hormones can be medically appropriate in certain situations—such as sensitivity to specific fillers, the need for custom combinations, or unique dosage requirements—the FDA maintains that commercial, FDA-approved estradiol and progesterone products should be used whenever possible.

At Gemini Health & Wellness, we use compounded therapies thoughtfully and only when clinically justified, always prioritizing patient safety and evidence-based care.

What These Changes Mean for Current Hormone Therapy Patients

For individuals already taking hormone therapy, the updated FDA guidelines may not change their regimen directly, but they do improve the clarity and accuracy of risk discussions. Many patients experience a sense of relief knowing their treatment is aligned with the very research that motivated these changes. Consent forms, educational materials, and clinical conversations will now better reflect the true risk-benefit profile of hormone therapy rather than outdated assumptions.

Patients may also find greater comfort and confidence in their therapy as the FDA’s updates help normalize the use of hormone therapy as a safe, appropriate, and science-backed option for symptom relief and wellness.

What These Changes Mean for Those Hesitating to Start Hormone Therapy

If you have hesitated to start hormone therapy due to fear of cancer, stroke, or long-term disease risk, these new FDA changes may provide the clarity needed to reconsider. Many women have endured years of hot flashes, low energy, mood changes, and reduced sexual well-being because the previous warnings created unnecessary alarm.

The new labeling acknowledges that hormone therapy can be used safely when prescribed at the right time, in the right dose, and with proper monitoring. It shifts the narrative dramatically from “hormones are dangerous” to “hormones can be safe and effective for the right patient with thoughtful oversight.”

This balanced perspective allows women to explore treatment options without the fear that once dominated the conversation.

The Gemini Health & Wellness Approach to Hormone Therapy

Our approach at Gemini Health & Wellness has always aligned with the principles reflected in the FDA’s updated guidance. We believe in personalized care grounded in science, safety, and patient empowerment. Every hormone therapy consultation includes a comprehensive health evaluation, lab testing, discussion of goals, and careful consideration of risks and benefits.

We offer FDA-approved estradiol and micronized progesterone therapies, testosterone therapy for medically confirmed hypogonadism, non-hormonal menopausal options, peptide therapy when appropriate, and carefully selected compounded therapies when needed. Ongoing follow-up and lab monitoring ensure that each patient receives care tailored to their unique physiology and goals.

Our mission is to help patients feel their best—physically, emotionally, and mentally—using tools that are supported by science and guided by individualized care.

A New Chapter in Hormone Health

The FDA’s 2025 hormone therapy updates represent a long-overdue alignment between regulatory language and modern medical evidence. These changes restore balance and clarity to a field that has been overshadowed by misunderstanding for too long.

Hormone therapy is not a cure-all, and it is not right for everyone. But for millions of women and men seeking relief from disruptive symptoms, improved quality of life, and better long-term wellness, hormone therapy is a powerful, well-studied, and now more accurately represented treatment option.

If you are ready to explore hormone therapy—or revisit a conversation you once set aside—we invite you to connect with us at Gemini Health & Wellness. With the new FDA changes, the path toward safe, effective symptom relief has never been clearer.

References

1. U.S. Food and Drug Administration (FDA). FDA Announces Updated Labeling for Menopausal Hormone Therapy Products. FDA Press Release, 2025.
2. U.S. Department of Health & Human Services (HHS). HHS Updates Safety Information for Hormone Therapy to Reflect Modern Evidence. 2025 Announcement.
3. Women’s Health Initiative (WHI) Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288(3):321–333.
4. Manson, J.E., et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the WHI trials. JAMA.
5. North American Menopause Society (NAMS). 2022–2023 Hormone Therapy Position Statement.
6. American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin: Menopausal Hormone Therapy. Updated clinical guidance.
7. FDA Drug Safety Communication. Testosterone Therapy: Updated Class Labeling Based on the TRAVERSE Trial. FDA, 2025.
8. TRAVERSE Trial Investigators. Cardiovascular Safety of Testosterone Replacement Therapy. New England Journal of Medicine.
9. FDA Consumer Information. Menopause & Hormones: Common Questions and Answers About Menopausal Hormone Therapy. Updated 2023–2025.
10. VA Clinical Guidance. Use of Compounded Bioidentical Hormone Therapy. Department of Veterans Affairs, 2025.
11. Endocrine Society. Clinical Practice Guideline on Testosterone Therapy for Hypogonadism.
12. Elinzanetant Approval Summary. FDA Non-Hormonal Therapy Approval for VMS, 2025.